MICSI develops advanced image enhancement and quantification software for MRI and PET. Its FDA-cleared MICSI-RMT platform leverages physics-based denoising to deliver clearer, more reliable MRI images. The new MICSI-PET solution extends this technology to PET imaging, enabling automated, MRI-guided denoising, super-resolution, and quantitative biomarker mapping for Amyloid, Tau, and FDG studies. MICSI empowers hospitals, imaging centers, and research institutions to achieve superior image quality, reproducible quantification, and streamlined workflows for Alzheimer’s disease and beyond.